letrozole moa | Letrozole: Uses, Interactions, Mechanism of Action

Keyword	CPC	PCC	Volume	Score	Length of keyword
letrozole moa	0.68	0.6	3243	35	13
letrozole	1.58	0.2	5816	75	9
moa	0.32	1	6712	85	3

Keyword	CPC	PCC	Volume	Score
letrozole moa	0.95	0.5	4677	59
letrozole moa fertility	1.66	0.4	9903	71
letrozole moa infertility	0.12	0.3	140	55
letrozole medication moa	1.31	0.8	9292	71

Search Results related to letrozole moa on Search Engine

Letrozole: Uses, Interactions, Mechanism of Action | DrugBank …
drugbank.com

https://go.drugbank.com/drugs/DB01006

WEBPharmacology. Indication. Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. 9 Letrozole, given with ribociclib, …

DA: 95 PA: 23 MOZ Rank: 35

The discovery and mechanism of action of letrozole - PMC
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001216/

WEBOct 3, 2007 · The discovery of letrozole (Femara ®) achieved the goal of discovering a highly potent and totally selective AI. Letrozole has greater potency than other AIs, including anastrozole, exemestane, formestane, and aminoglutethimide.

DA: 6 PA: 49 MOZ Rank: 84

Aromatase Inhibitors - StatPearls - NCBI Bookshelf
nih.gov

https://www.ncbi.nlm.nih.gov/books/NBK557856/

WEBJul 4, 2023 · Letrozole is also a selective aromatase inhibitor. It is manufactured in 2.5 mg tablets. For postmenopausal breast cancer, dosing is 2.5 mg daily. As an agent to induce ovulation, dosing is 2.5 mg to 5 mg daily for 5 days starting on day 3 of the menstrual cycle.

DA: 5 PA: 15 MOZ Rank: 33

Letrozole - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Letrozole

WEBLetrozole, sold under the brand name Femara among others, is an aromatase inhibitor medication that is used in the treatment of breast cancer. [1] It was patented in 1986 and approved for medical use in 1996. [4] . In 2021, it was the 222nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.

DA: 41 PA: 46 MOZ Rank: 79

Letrozole: Dosage, Mechanism/Onset of Action, Half-Life
medicine.com

https://www.medicine.com/drug/letrozole/hcp

WEBFeb 17, 2020 · Last updated December 18, 2019. Includes Letrozole indications, dosage/administration, pharmacology, mechanism/onset/duration of action, half-life, dosage forms, interactions, warnings, adverse reactions, off-label uses and more.

DA: 15 PA: 20 MOZ Rank: 54

The discovery and mechanism of action of letrozole.
drugbank.com

https://go.drugbank.com/articles/A190546

WEBStudies with MCF-7Ca xenografts successfully predicted that letrozole would be clinically superior to the previous gold standard tamoxifen and also indicated that it may be more effective than other AIs.

DA: 35 PA: 63 MOZ Rank: 65

Letrozole: Pharmacology, toxicity and potential therapeutic effects
sciencedirect.com

https://www.sciencedirect.com/science/article/pii/S0024320522007743

WEBDec 1, 2022 · Abstract. The highly active estrogen metabolism and receptor protein expression are to blame for the elevated breast cancer (BC) rate in post-menopausal women. Letrozole is a powerful endocrine medication that targets and inhibits the aromatase, often known as an aromatase inhibitor (AI).

DA: 8 PA: 88 MOZ Rank: 50

A Randomized Trial of Letrozole in Postmenopausal Women after …
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa032312

WEBNov 6, 2003 · The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy. Methods.

DA: 69 PA: 46 MOZ Rank: 93

Letrozole: Advancing Hormone Therapy in Breast Cancer
sagepub.com

https://journals.sagepub.com/doi/10.2217/WHE.12.49

WEBNov 1, 2012 · Letrozole is a type 2 aromatase inhibitor, which reduces availability of estrogen in postmenopausal women, thereby decreasing its ability to stimulate breast cancer cells. Phase III trials in both the advanced and early breast cancer setting have shown an improvement in disease-free survival compared with other compounds, …

DA: 40 PA: 23 MOZ Rank: 47

Letrozole: Pharmacology, toxicity and potential therapeutic effects
nih.gov

https://pubmed.ncbi.nlm.nih.gov/36243120/

WEBDec 1, 2022 · Letrozole is a powerful endocrine medication that targets and inhibits the aromatase, often known as an aromatase inhibitor (AI). It aids in the adjuvant, neoadjuvant, and metastatic treatment of HR+ breast cancer because it can boost FSH production for ovulation induction.

DA: 13 PA: 35 MOZ Rank: 81